Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Reports Q1 2024 Financial Results and Business Update
Summary
Crinetics Pharmaceuticals, Inc. reported financial results for the first quarter of 2024, showcasing positive topline results from Phase 3 and Phase 2 studies for paltusotine in acromegaly and carcinoid syndrome, respectively. The company also announced a private placement financing of $350 million to support ongoing operations and clinical trials. Additionally, Crinetics plans to present initial results from Phase 2 studies of atumelnant at the Endocrine Society's annual meeting in June 2024 and expects to submit a New Drug Application (NDA) for paltusotine in acromegaly in the second half of 2024.
Profitelligence Alerts
Get alerts for CRNX
Be first to know when Crinetics Pharmaceuticals Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the development of novel therapeutics for patients with endocrine conditions and other rare diseases. The primary focus of Crinetics is on crafting oral therapies that target hormone receptors, offering significant potential to transform the treatment landscape for several disorders. The company's pipeline includes investigational drugs such as paltusotine and CRN04894, aimed at addressing conditions like acromegaly and congenital adrenal hyperplasia, respectively. Crinetics combines cutting-edge drug discovery with an in-depth understanding of disease biology to impact the field of endocrinology substantially. By specializing in small molecules, Crinetics Pharmaceuticals seeks to provide new treatment options that enhance patient quality of life and address significant unmet medical needs. Headquartered in San Diego, California, the enterprise collaborates with academic institutions and industry partners to position its innovations at the forefront of medical advancement. Its work holds significant potential to influence the pharmaceutical industry, contributing to the expansion of targeted therapies within niche markets where few options currently exist.
Official SEC Documents
Advertisement